KALV
KalVista Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.00
+0.00%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -530.25x
- Price / sales
- 6.52x
- Price / cash flow
- 39.41x
Enterprise value
- Enterprise value
- $1.4B
- EV / sales
- 6.44x
- EV / EBITDA
- -30.75x
- EV / EBIT
- -23.09x
- Market cap
- $1.4B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026